{"entity":{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","aka":["Blood Cancer Journal","Blood Cancer J"],"tldr":"Blood Cancer Journal is a fully open access Nature Portfolio journal on leukaemia, lymphoma, myeloma and related disorders, read by clinical and laboratory haematologists.","summary":"Blood Cancer Journal has been published since 2011 by Nature Publishing Group, now part of Springer Nature, from New York. Its homepage describes a peer-reviewed, fully open access journal dedicated to articles of the highest quality on haematological malignancies and related disorders, considering original research, reviews, guidelines and letters, and it runs a Current Treatment Algorithms article type that gives concise treatment pathways for blood cancers. It is listed in DOAJ with CC BY and CC BY-NC-ND licences, an article processing charge and anonymous peer review. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.nature.com/bcj/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101568469"},{"label":"DOAJ record","url":"https://doaj.org/toc/2044-5385"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Nature Portfolio)","url":"https://www.nature.com/bcj/","issn":"2044-5385","scope":"haematological oncology","access":"open-access","founded":2011,"matchNames":["Blood Cancer J","Blood cancer journal","Blood Cancer Journal"]},"route":"/journals/blood-cancer-journal/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"person":[{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/"},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/"},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/"}],"paper":[{"id":"paper-mateos-20-2-20-smouldering-bcj-2020","kind":"paper","name":"IMWG 20/2/20 risk stratification model for smouldering multiple myeloma","route":"/key-papers/paper-mateos-20-2-20-smouldering-bcj-2020/"},{"id":"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021","kind":"paper","name":"IMWG consensus definition of primary plasma cell leukaemia at 5 percent circulating plasma cells","route":"/key-papers/paper-imwg-plasma-cell-leukaemia-definition-bcj-2021/"},{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/"}]}}